Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

A new multi-test approach may spot hidden blood vessel damage before symptoms appear

NCT ID NCT06325800

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This observational study is testing whether a combination of non-invasive measurements—including blood pressure monitoring, ultrasound, blood and urine tests, and a light-based technique called photoplethysmography—can detect early damage to blood vessels and organs in adults at increased cardiovascular risk. The study will enroll about 1,000 participants and will not assign any treatments. The goal is to see which markers and devices are reliable and whether they can improve early risk assessment and prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multimodal cardiovascular phenotyping (non-invasive imaging, blood/urine biomarkers, photoplethysmography)
What this could lead to
If successful, this could lead to better tools for early detection of vascular damage, improving cardiovascular risk assessment and prevention.
What could go wrong
This is an observational study, so it won't test treatments. The measurements may not prove reliable or improve prediction beyond existing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be selected from adults evaluated in outpatient Internal Medicine, Hypertension, and Cardiovascular Risk clinics at the Complejo Hospitalario Universitario de Santiago de Compostela, A Coruña, Spain. The source population includes people referred from primary care or other hospital services for assessment of elevated blood pressure, hypertension, cardiovascular risk factors, suspected subclinical target-organ damage, or non-invasive vascular evaluation. Eligible participants are enrolled consecutively whenever possible. The registry reflects routine clinical practice and may include both newly evaluated participants and individuals previously characterized under the applicable protocol who have provided the required informed consent.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA * Age 18 years or older. * Written informed consent to participate in the registry. * Undergoing cardiovascular risk or hypertension assessment in a primary-prevention setting. * At least one of the following cardiovascular risk conditions: * Confirmed hypertension requiring specialist cardiovascular assessment. * A SCORE2 estimated 10-year cardiovascular risk of 2% or higher in participants aged 40 to 69 years, when SCORE2 is applicable. * A SCORE2-OP estimated 10-year cardiovascular risk of 2% or higher in participants aged 70 to 89 years, when SCORE2-OP is applicable. * Type 2 diabetes with at least moderate cardiovascular risk according to SCORE2-Diabetes in participants within its validated age range, or according to guideline-defined clinical risk criteria when SCORE2-Diabetes is not applicable. * Chronic kidney disease confirmed for at least 3 months, defined by an estimated glomerular filtration rate below 60 mL/min/1.73 m², a urinary albumin-to-creatinine ratio of 30 mg/g or higher, or another persistent marker of kidney damage. * Hypertension-mediated target-organ damage or subclinical atherosclerotic vascular disease documented by clinical, laboratory, imaging, or functional assessment. * Confirmed or probable familial hypercholesterolemia. * For participants aged 18 to 39 years or older than 89 years, a documented major cardiovascular risk condition, such as hypertension, type 2 diabetes, chronic kidney disease, familial hypercholesterolemia, or target-organ damage. EXCLUSION CRITERIA * Inability or unwillingness to provide written informed consent. * Established clinical cardiovascular disease requiring secondary-prevention management, including previous myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack, coronary or peripheral revascularization, symptomatic peripheral artery disease, or other established symptomatic cardiovascular disease. * Acute or clinically unstable illness that prevents completion of the baseline registry assessment. * A medical, technical, cognitive, or logistical condition that prevents completion of the minimum required registry procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Hospitalario Universitario de Santiago de Compostela

    RECRUITING

    Santiago de Compostela, A Coruña, 15706, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.